Jorge Dimartino

Jorge DiMartino currently serves as the Chief Medical Officer and Executive Vice President of Clinical and Translational Development at Plexium since October 2024, and as the Founder and Principal at Fairway Oncology R&D Consulting since March 2024, focusing on anti-cancer drug development. Prior experience includes serving as Chief Medical Officer at Kronos Bio, Inc. from December 2019 to March 2024, and Vice President of Translational Development at Celgene from April 2011 to December 2019, where responsibilities included leadership of the Epigenetics Center of Excellence and oversight of oncology trial development. Earlier roles include Executive Director of Translational Development at Celgene and Group Medical Director at Genentech, leading initiatives for early-stage oncology compounds. Jorge DiMartino holds a Ph.D. in Immunology from Cornell University Graduate School of Medical Sciences and completed a residency and heme/onc fellowship at Stanford University School of Medicine.